A magnified coronavirus germ illustration sits beside laboratory glassware during coronavirus vaccine research work inside the Pasteur Institute laboratories in Lille, France, on Monday, March 9, 2020. The euro-area economy may be headed for its first recession in seven years as the coronavirus outbreak takes an increasing toll on businesses and consumer confidence. Photographer: Adrienne Surprenant/Bloomberg via Getty Images
Long before vaccines became a thing, inoculation which is intentionally introducing a pathogen or antigen that can cause a disease into a living organism to stimulate the production of antibodies was current practice in Africa, China and India some 2,000 years ago.
According to The National Centre for Biotechnology Information (NCBI), smallpox, caused by the variola virus, appeared around 10,000 BC, at the time of the first agricultural settlements in north-eastern Africa. The virus spread around the world with disastrous effects on humankind; yet, survivors of smallpox seemed to then be immune from the virus.
This is when inoculation, also called variolation, started. The inoculator usually used a lancet wet with fresh matter taken from a ripe pustule of some person who suffered from smallpox. The material was then subcutaneously introduced on the arms or legs of the non-immune person, says NCBI. And the practice had some degree of effectiveness. Many inoculated people did become immune to smallpox, but some also died while others even started a new epidemic.
Still, there was hope and by 1796 British physician Edward Jenner, who had observed how milkmaids were generally immune to smallpox he assumed this was probably because of the pus in the blisters that milkmaids received from cowpox (a disease similar to smallpox, but much less virulent), decided to insert pus from a cowpox pustule into an eight-year-old boys arm.
The boy not only survived the experiment but also became immune to smallpox. Although the experiment proved conclusive, the vaccine wasnt born yet. The Royal Society, the UKs scientific academy, needed more proof and vaccination only became widespread two years later. And it took almost another two centuries to eradicate the smallpox entirely; it was eliminated in 1979, with the last case seen in Somalia two years earlier.
Today, as Covid-19 rapidly spreads across the world, the search for a vaccine against the novel virus is hastening. An article published by The Guardian newspaper on 25 March explained that: About 35 companies and academic institutions are racing to create a vaccine, at least four of which already have candidates they have been testing in animals. The first of these produced by Boston-based biotech firm Moderna will enter human trials imminently.
The process to create a vaccine is a complex one: as the Institut Pasteur in France explains, scientists need to understand more about the virus, the face of the virus, in order to recreate the pathogen and extract antigens, the virus toxins that spark an immune response in the body, and hopefully find antibodies that may have therapeutic applications.
The Guardian Laura Spinney reported that this process can be achieved by using live, weakened forms of the virus, or part or whole of the virus once it has been inactivated by heat or chemicals.
Professor Ed Rybicki, from the Department of Molecular & Cell Biology and Institute of Infectious Disease and Molecular Medicine at the University of Cape Town, adds that novel viruses require experimental investigational work, such as growing the novel virus in culture which is often not easy characterising it by sequencing it, fortunately [it is] very quick these days, and can be done without culturing it, then by looking at its components and how they relate to known viruses.
Yet, as it sometimes happened with inoculation, the live form can continue to evolve in the host, for example, potentially recapturing some of its virulence and making the recipient sick, while higher or repeat doses of the inactivated virus are required to achieve the necessary degree of protection.
Another option, Spinney notes, is to extract the genetic code for the protein spike on the surface of Sars-CoV-2 (Covid-19), which is the part of the virus most likely to provoke an immune reaction in humans, and pasting it into the genome of a bacterium or yeast forcing these microorganisms to churn out large quantities of the protein.
It can take years to find the right vaccine and although few companies and institutes around the world have already started human trials, results will only be known in a few months without any assurance that theyll work.
Rybicki explains that the human testing phases, following quite extensive animal testing for toxicity, immunogenicity and dosing, are broken into three phases:
First, there needs to be safety trials in a few human volunteers; 20-80 people, healthy volunteers who are monitored for reaction frequently. Some data can be gathered on immunogenicity in these trials, says Rybicki.
The second step is trials over several hundred people screened by strict criteria, usually not in a disease risk group, where more safety but also primarily immunogenicity and dosing schedule and amounts are trialled. These trials generally include randomized dosing, with placebo groups.
Finally, Efficacy trials, on thousand or multiple thousands of people, in at-risk groups of people; randomised double-blind placebo-controlled trials, that look for lower incidence of infection in vaccinated vs placebo groups generally after the trial is finished.
But there can be many hiccups along the way. Rybicki says the main challenges are investigation of the components of the virus, getting them made, and money to do the work!
In the case of Covid-19, the challenge is also the novelty of the virus. Spinney explains that In contrast, Sars-CoV-2 is a novel pathogen in humans, and many of the technologies being used to build vaccines are relatively untested too. No vaccine made from genetic material RNA or DNA has been approved to date, for example. So the Covid-19 vaccine candidates have to be treated as brand new vaccines.
When asked about collaborations between institutes and research centres around the world, Rybicki says that: A collaboration between various centres is proposed; what is happening right now in terms of response is a scramble to develop and roll out tests mainly nucleic-acid based by the NICD and partners, and to sequence virus isolates by NICD and various academic groups.
We started quite early here at UCT with proposing a South African programme for vaccine development: this would have involved mine and Professor Anna-Lise Williamsons groups and partners like Professor Wolfgang Preiser at Stellenbosch University, in making several candidate vaccines (our groups) and doing neutralisation tests on animal serum injected with these candidates (Preiser). We expanded this into a proposal to Department of Science and Innovation (DSI) which included Professors Jonathan Blackburn, Ed Sturrock, Wendy Burgers and Dr Mani Margolin from UCT, which aimed at a One Health type of approach, where we would produce and test proteins as possible components of serological test kits, some of which could also be used as vaccines. This got subsumed by a national effort apparently led by the South African Medical Research Council (SAMRC) and DSI on trying to co-ordinate response efforts which seem to have as their priority the development and deployment of PCR-based testing, with serological reagent provision very necessary for bedside blood tests and testing to see who is already immune more on a back burner, and vaccines a maybe for the future.
On the progress made, Rybicki explains that their group has been able to create through cell culture and plants a candidate reagent or vaccine based on the S or spike protein of SARS-CoV-2. He is confident that this could give the basis of a reagent supply to other institutions or companies for the formulation of serological assays. ML
If you would like to share your ideas or suggestions with us, please leave a comment below or email us at [emailprotected] and [emailprotected].
Sign up for our newsletter to get the best of Maverick Life delivered to your inbox every Sunday morning
Please note you must be a Maverick Insider to comment. Sign up here or if you are already an Insider.
Read more from the original source:
Vaccines: what are they and how do they work? - Daily Maverick
- Podcast 9 Athens part 3 and news - November 8th, 2009 [November 8th, 2009]
- Podcast 10 Athens part 4 - November 8th, 2009 [November 8th, 2009]
- Podcast 11 Athens Part 5 - November 8th, 2009 [November 8th, 2009]
- Episode 12 Cardiac Nuclear Medicine in the UK - November 8th, 2009 [November 8th, 2009]
- Podcast 13 Choline PET and prostate cancer - November 8th, 2009 [November 8th, 2009]
- Episode14 ED function and Dysponea - November 8th, 2009 [November 8th, 2009]
- ep 15 Collimator Choice and Reconstruction algorithm - November 8th, 2009 [November 8th, 2009]
- Episode 16 Dr Strauss on vulnerable plaque - November 8th, 2009 [November 8th, 2009]
- Episode17 Chemical Stress - November 8th, 2009 [November 8th, 2009]
- Episode 18 Myocardial Perfusion Imaging and Diabetes - November 8th, 2009 [November 8th, 2009]
- Episode 19 The INSPIRE trial - November 8th, 2009 [November 8th, 2009]
- 20 Dual isotope with a difference - November 8th, 2009 [November 8th, 2009]
- Episode 21 The real effect of stress - November 8th, 2009 [November 8th, 2009]
- Episode 22 D-SPECT - November 8th, 2009 [November 8th, 2009]
- Episode 23 VQ Reprise - November 8th, 2009 [November 8th, 2009]
- Episode 24 Hepatobiliary Nuclear Medicine - November 8th, 2009 [November 8th, 2009]
- Episode 25 Sleep Apnea - November 8th, 2009 [November 8th, 2009]
- Episode 26 Imaging Post Traumatic Stress Disorder - November 8th, 2009 [November 8th, 2009]
- Episode 27 Cardiac Stem Cells - November 8th, 2009 [November 8th, 2009]
- Episode 28 Molly Supply - November 8th, 2009 [November 8th, 2009]
- Episode 29 Melanoma therapy interview with Dr Ekaterina Dadachova - November 8th, 2009 [November 8th, 2009]
- Episode 30 Viral Therapy - November 8th, 2009 [November 8th, 2009]
- Episode 31 breast radiotherapy using radioisotopes - November 8th, 2009 [November 8th, 2009]
- Episode 32 news from snm - November 8th, 2009 [November 8th, 2009]
- Episode 33 EBV Imaging and Therapy - November 8th, 2009 [November 8th, 2009]
- Episode 34 Dr Lele SNM India 2009 - December 14th, 2009 [December 14th, 2009]
- Episode 35 Dr Andrew Scott from the Ludwig institute - January 10th, 2010 [January 10th, 2010]
- Episode 36 CardiArc - February 25th, 2010 [February 25th, 2010]
- Episode 37 Dr Modder Radiosynoviorthesis (Radiation Synovectomy) - March 31st, 2010 [March 31st, 2010]
- Episode 38 Indian Nuclear Medicine With Dr Malhotra and Dr Krishna - May 28th, 2010 [May 28th, 2010]
- Episode 39 Prof Ora Israel The Utility of Hybrid Imaging - July 13th, 2010 [July 13th, 2010]
- Episode 40 New V/Q SPECT developments - October 11th, 2010 [October 11th, 2010]
- Episode 41 scintimun - February 14th, 2011 [February 14th, 2011]
- Episode 42 Radio-Isotope Supply into the future - March 6th, 2011 [March 6th, 2011]
- Podcast 4: DNA therapy - April 24th, 2011 [April 24th, 2011]
- Sorry about the delay a new podcast will be out soon! - April 24th, 2011 [April 24th, 2011]
- Podcast 5 Flash 3D - April 24th, 2011 [April 24th, 2011]
- Podcast 6 Affibody - April 24th, 2011 [April 24th, 2011]
- Podcast 7 EANM 2006 Athens Part 1 - April 24th, 2011 [April 24th, 2011]
- Podcast 8 Athens Part 2 - April 24th, 2011 [April 24th, 2011]
- Episode 43 Rapidscan Part 1, 720P high quality video version - May 1st, 2011 [May 1st, 2011]
- Episode 43 Rapidscan Part 1, Ipod quality video - May 1st, 2011 [May 1st, 2011]
- Episode 43 Rapidscan Part 1, Audio version - May 1st, 2011 [May 1st, 2011]
- Episode 45 Mummies with cardiovascular disease video - May 21st, 2011 [May 21st, 2011]
- Episode 45 Mummies with cardiovascular disease audio edition - May 21st, 2011 [May 21st, 2011]
- Episode 46 Dr Gordon DePuey Choosing Reconstruction clinical perspective - August 7th, 2011 [August 7th, 2011]
- Episode 46 Dr Gordon DePuey Choosing Reconstruction clinical perspective audio version - August 7th, 2011 [August 7th, 2011]
- Episode 47 Cardiac Image Fusion With Dr Kaufmann - September 18th, 2011 [September 18th, 2011]
- Episode 47 Cardiac Fusion with Dr Kaufmann video version - September 18th, 2011 [September 18th, 2011]
- Dear Steve, I am and many more like me are your one more thing. - October 9th, 2011 [October 9th, 2011]
- EPISODE 48 PET MRI camera from Siemens with Dr Georgi audio - October 23rd, 2011 [October 23rd, 2011]
- EPISODE 48 PET MRI camera from Siemens Dr Georgi video - October 23rd, 2011 [October 23rd, 2011]
- Silicon Biosystems to Present Single-Circulating Tumor Cell Molecular Characterization at the Fourth World CTC Summit - April 25th, 2012 [April 25th, 2012]
- Leukaemia cells have a remembrance of things past - April 25th, 2012 [April 25th, 2012]
- Technologist Education Requirements Can Help Cut Repeat Scans - April 25th, 2012 [April 25th, 2012]
- HKU Collaborative Research Discovers A Novel Molecular Mechanism Of A New Anti-HIV-1 Drug Candidate - April 25th, 2012 [April 25th, 2012]
- Focal Segmental Glomerulosclerosis and the Nephrotic Syndrome - Part 1 Clinical - Video - May 4th, 2012 [May 4th, 2012]
- Electro-Medicine : Biological Physics - The Molecular Basis of Alzheimers Disease - Video - May 4th, 2012 [May 4th, 2012]
- osdd heterocyclic compounds and molecular medicines - Video - May 4th, 2012 [May 4th, 2012]
- Molecule to Medicine: The Biomarker Frontier - Video - May 4th, 2012 [May 4th, 2012]
- Fulfilling the Promise of Molecular Medicine in a Developmental Brain Disorder - Video - May 4th, 2012 [May 4th, 2012]
- Focus on Stefanie Dimmeler - Video - May 4th, 2012 [May 4th, 2012]
- Dundee - May 4th, 2012 [May 4th, 2012]
- Nanotechnology In Medicine: Huge Potential, But What Are The Risks? - May 5th, 2012 [May 5th, 2012]
- Cutting Edge Technology Coming To DMH - May 5th, 2012 [May 5th, 2012]
- This Week in Experimental and Molecular Pathology - May 5th, 2012 [May 5th, 2012]
- Researchers' discovery offers hope for cancer, heart disease miracle drugs - May 7th, 2012 [May 7th, 2012]
- Penn State student Zachary Hostetler from Garnet Valley is being honored as a student marshal - May 7th, 2012 [May 7th, 2012]
- NCKU Student Wins Prestigious Award for Anti-Cancer Research - May 10th, 2012 [May 10th, 2012]
- In-Vitro Diagnostics (IVD) Market (Clinical Chemistry, Immunoassays, Molecular Diagnostics, Hematology Analyzers ... - May 10th, 2012 [May 10th, 2012]
- Pitt team uses genomics to identify a molecular-based treatment for a viral skin cancer - May 10th, 2012 [May 10th, 2012]
- Genomics used to identify a molecular-based treatment for a viral skin cancer - May 10th, 2012 [May 10th, 2012]
- 2 molecular biologists get $500K medical prize - May 13th, 2012 [May 13th, 2012]
- 2 molecular biologists share $500K medical prize - May 13th, 2012 [May 13th, 2012]
- Lab21 Unveils New Molecular Analysis Services at Greenville Site - May 13th, 2012 [May 13th, 2012]
- 2 molecular biologists from NYC to share $500K medical prize for pioneering research on cells - May 13th, 2012 [May 13th, 2012]
- Two Molecular Biologists Get $500K Medical Prize - May 13th, 2012 [May 13th, 2012]
- Pair of molecular biologists receive Albany Medical Center Prize - May 13th, 2012 [May 13th, 2012]
- CNIO scientists successfully test the first gene therapy against aging-associated decline - May 16th, 2012 [May 16th, 2012]
- Cancer Institute of New Jersey Aims to Advance Personalized Cancer Treatments Through 'Precision Medicine' - May 16th, 2012 [May 16th, 2012]